Steve Mason

Apotex brought a motion to amend its pleadings in an ongoing patent dispute over the drug Lansoprazole.

Following the Supreme Court's rejection of the 'Promise Doctrine' in AstraZeneca, Apotex sought to recast its previous Promise Doctrine allegations as claims of insufficiency, overbreadth, and fraud under sections 27 and 53 of the Patent Act.

The court dismissed the motion, finding that the proposed amendments were legally untenable and merely repackaged the defunct Promise Doctrine.

Furthermore, the court held that the fraud allegations lacked the strict particularity required by the Rules of Civil Procedure and awarded elevated costs to the respondents.

The defendants sought leave to appeal a decision dismissing their Rule 21 motion to strike the plaintiff's amended statement of claim.

The defendants argued that the plaintiff was not entitled to seek declaratory relief under Canadian or American law.

The Divisional Court dismissed the application for leave to appeal, finding no conflicting decisions or reason to doubt the correctness of the motions judge's decision.

The court noted that issues regarding the applicability of US law to a cross-border declaration could be litigated later in a motion for summary judgment.